IndustryCompany release

SI-BONE Q3 revenue rises 14.5% to $55.7M, holds 2026 guidance

🇺🇸 SI-BONE, Inc. (SIBN) · Mon 02 Nov 2026

The spinal and pelvic device maker reported narrower losses and positive adjusted EBITDA, citing a September FDA 510(k) clearance and new October hospital payment categories.

SI-BONE reported third-quarter 2026 results on 2 November, with worldwide revenue of $55.7M, up 14.5%. US procedure volume grew by about 19.5%, according to the company.

The net loss narrowed to $3.6M, and adjusted EBITDA was positive at $3.0M. The company reaffirmed its 2026 revenue guidance of $231M to $233M, while lowering its expected growth in operating expenses to about 10.5%.

On the regulatory front, SI-BONE pointed to FDA 510(k) clearance in September for iFuse Granite Onyx. The device carries a breakthrough designation and is intended for spine fusion failures. For context, a 510(k) clearance means FDA has found a device substantially equivalent to a legally marketed predicate; it is not a premarket approval.

On reimbursement, new Medicare Severity Diagnosis Related Groups (MS-DRGs) took effect in October. The company said these raise hospital payments for complex spinal fusions using iFuse Bedrock Granite by up to about $50,000.

What it means for your team

  • Market-access teams should note the new MS-DRGs effective in October, which the company says increase hospital payments for complex spinal fusions using iFuse Bedrock Granite.
  • Regulatory teams can track the September 510(k) clearance of iFuse Granite Onyx, a breakthrough-designated device, as an example of a fusion-failure indication reaching the US market.
  • The unchanged revenue guidance and trimmed opex outlook indicate the company expects to keep growing while containing costs.

Company's press release (SEC filing): SI-BONE, Inc. ↗

Article written by VigiEye from the official source (SI-BONE, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →